The individualised plan for the clinical management of breast cancer currently still relies on traditional prognostic and predictive factors, including clinical, histological and some well-defined biological factors such as hormone receptors: ER (oestrogen receptor), PR (progesterone receptor) and HER2 (human epidermal growth factor receptor 2) expression [3]. Here, ERBB2 is linked to breast carcinoma.